Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE: CATX) provided its full year 2024 results and business highlights, reporting strong progress across its clinical programs. The company maintains a robust cash position of $227 million as of December 31, 2024, expected to fund operations into late 2026.

Key developments include:

• VMT-α-NET trial enrolled 30 patients through February 2025 in Cohort 2, with promising early safety and efficacy data
• First-in-human combination dosing of VMT01 with nivolumab achieved in March 2025
• IND clearance received for PSV359 targeting FAP-α, with first patient dosing expected mid-2025
• Expansion of manufacturing capabilities through facility acquisitions in Houston, Chicago, and Los Angeles for $20.7 million
• €49.0 million equipment and services agreement with Comecer SpA for production facilities

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the dosing of the first patient in a new cohort of their Phase 1/2a trial combining [212Pb]VMT01, their targeted alpha-particle therapy (TAT), with Bristol Myers Squibb's nivolumab (Opdivo®) for MC1R-positive metastatic melanoma patients.

The new cohort will receive [212Pb]VMT01 at 1.5 mCi alongside nivolumab, following earlier cohorts where [212Pb]VMT01 was administered as monotherapy. Initial results from previous cohorts, presented at the Society for Melanoma Research Congress in October 2024, showed promising outcomes with:

• No dose-limiting toxicities observed
• Early signs of anti-tumor activity in heavily pretreated patients

The company aims to explore how lower-dose radiopharmaceuticals can be optimized when combined with immunotherapies to potentially enhance both safety and efficacy for patients with treatment options.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical development company focused on advanced cancer treatments, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, from 11:10 AM to 11:40 AM ET. Additionally, they will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11, 2025, from 3:30 PM to 3:55 PM ET.

Both events will be accessible via webcast, with replays available for 90 days through the Investors page on Perspective's website.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical development company focused on advanced cancer treatments, announced it will release its full year 2024 financial results and provide a business update on March 26, 2025, after market close. The financial report and business update will be accessible through the company's website newsroom section.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has announced its participation in two major investor conferences in February 2025.

The company will attend Oppenheimer's 35th Annual Healthcare Life Sciences Conference, featuring a virtual fireside chat on Wednesday, February 12, 2025, from 2:00 p.m. to 2:30 p.m. ET. Additionally, they will participate in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York, NY on Friday, February 28, 2025.

Senior leadership team members will be available for one-on-one meetings with investors at both events. Webcasts will be accessible live and archived for 90 days through the Investors page on Perspective's website.

Perspective Therapeutics (NYSE: CATX) presented updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Gastrointestinal Cancers Symposium. The trial focuses on patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors.

Key findings from nine patients in Cohorts 1 (2.5 mCi) and 2 (5.0 mCi) show: no dose-limiting toxicities, favorable safety profile, and promising efficacy. Three of seven patients in Cohort 2 experienced objective responses, with one confirmed response lasting 17 weeks. Five patients maintain stable disease.

The Safety Monitoring Committee supported proceeding with Cohort 3 dose escalation and expanding Cohort 2 enrollment. As of December 31, 2024, 18 patients have been dosed in Cohort 2. The company awaits FDA alignment before proceeding with Cohort 3.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated interim results from their Phase 1/2a trial of [212Pb]VMT-α-NET will be presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025, in San Francisco. The presentation, titled 'Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs),' will be featured in Poster Session B.

The company will host a webcast conference call on January 24, 2025, at 8:00 am ET to discuss the presented data. Dr. Richard L. Wahl, lead investigator and Professor of Radiology at Washington University School of Medicine, will participate alongside the management team. The initial results were previously presented with data cut-off on October 31, 2024.

Perspective Therapeutics (NYSE AMERICAN: CATX) has provided strategic updates and priorities for the next 12-18 months. The company reported preliminary unaudited cash and equivalents of $227.8M as of December 31, 2024, expected to fund operations into late 2026.

The company is advancing three clinical programs: VMT-α-NET for neuroendocrine tumors, which has shown promising safety data and clinical activity in 18 patients; VMT01 for melanoma treatment, demonstrating favorable safety profile and some clinical responses; and PSV359, a new asset targeting FAP-α in solid tumors, with potential enrollment starting mid-2025.

Additionally, four new assets are being evaluated for IND development. The company is expanding its manufacturing capabilities through improving existing facilities and developing recently acquired sites.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in two major healthcare conferences in San Francisco.

CEO Thijs Spoor will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 3:45 p.m. to 4:25 p.m. PT at The Westin St. Francis Hotel's Elizabethan B room. Additionally, the company will present at the Biotech Showcase conference on Tuesday, January 14, 2025, at 1:30 p.m. PT, taking place at the Hilton San Francisco - Union Square's Yosemite A Ballroom.

The management team will be available for one-on-one meetings with investors and strategic partners at both conferences, with interested parties directed to contact events@perspectivetherapeutics.com for scheduling.